An FDA inspection of the company’s Irvine, California, facility from June 9, 2025, through June 26, 2025, led to the warning letter. In the letter, the FDA outlined deficiencies in the automated insulin delivery system maker’s response letters after the FDA shared its observations in the wake of the inspection.
Beta Bionics said in an SEC filing that the warning letter highlights non-conformities related to its quality management system, medical device reporting and correction and removals. The warning letter does not restrict the company’s ability to produce, market or distribute products. Beta Bionics can also continue to seek FDA clearance of new products, despite the warning. That could prove relevant as the company has its planned “Mint” patch pump in development.
The company has eyes on a 2027 launch for the patch pump. It said in its SEC filing that it does not expect the warning letter to impact that plan.
Beta Bionics said it “takes the observations described in the warning letter seriously, and is currently preparing a written response to the warning letter.” The company also said it already took several corrective actions in response to the letter. Those include improvements to the processes identified in the warning letter.
The regulatory scrutiny makes Beta Bionics one of a handful diabetes technology developer to receive an FDA warning letter within the last year. Dexcom faced a warning letter last year related to its manufacturing practices, while the FDA this week disclosed a warning for Abbott’s CGM manufacturing as well.
Beta Bionics is one of the largest diabetes tech companies in the world. Read more about them in our free Diabetes Technology Special Report.
This FDA warning letter also follows a recent analyst downgrade for Beta Bionics after preliminary fourth-quarter results fell shy of expectations.
Beta Bionics, which has completed its first full year as a public company following its IPO last year, reported expectations for at least 5,581 new patient starts for its iLet automated insulin delivery system. While that represents a 36% increase from last year, BofA analyst Travis Steed wrote in a report that this tally comes in 4% shy of Wall Street projections. Steed said analysts expected more momentum in new patient starts amid an “increasingly competitive” market.
However, the company still has potential upside with iLet and Mint, in spite of performance concerns and now the warning letter.
The iLet autonomous insulin delivery system streamlines diabetes management by reducing the burden on patients and physicians. It initially received FDA clearance in May 2023. iLet uses an adaptive, closed-loop algorithm that initializes with the user’s body weight and requires no additional insulin dosing parameters. The algorithm removes the need to manually adjust insulin pump therapy settings and variables.
Recent milestones include data on the use of the flagship iLet system in a “fully closed-loop” manner. The company also has effective formulary agreements in place with all major pharmacy benefit managers (PBMs) in the U.S. as of July.
